Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Baranyi, A; Meinitzer, A; Putz-Bankuti, C; Stauber, R; Kapfhammer, HP; Rothenhäusler, HB.
Asymmetric dimethylarginine responses during interferon-α-induced depression in patients with chronic hepatitis C infection.
Psychosom Med. 2014; 76(3):197-207
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Baranyi Andreas
Kapfhammer Hans-Peter
Meinitzer Andreas
Putz-Bankuti Csilla
Rothenhäusler Hans-Bernd
Stauber Rudolf
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
The aim of this study was to examine the association of depressive symptoms with asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA). Patients with chronic hepatitis C infection were examined during interferon-α (IFN-α) treatment, which is often associated with treatment-induced depression. The associations between IFN-α-induced depressive symptoms with ADMA and SDMA levels were prospectively investigated until 3 months after treatment. Psychiatric and biological assessments were obtained at six different time points: before, during (at 1, 3, 6, and 9 months), and after the end of IFN-α treatment. During IFN-α treatment, 22 (53.7%) patients fulfilled the criteria for a treatment-related depressive disorder at least once during treatment. The increase in ADMA levels from baseline (depression group: 0.63 [0.08] μM, no depression group: 0.69 [0.08] μM) in response to IFN-α treatment was considerably higher in patients with IFN-α treatment-induced depressive episodes compared with patients without treatment-induced depressive episodes (3 months after the start of treatment: depression group: 0.72 [0.08] μM, no depression group: 0.72 [0.11] μM; ADMA: repeated-measure design analysis of variance [time × depression]: F(5,151) = 2.446, p = .036). The increase in SDMA was not associated with treatment-induced depression. Depression in response to IFN-α treatment is associated with elevated ADMA levels. These findings are relevant to nitric oxide-related biological pathways linking depression to increased cardiovascular disease risk. Future studies are needed to clarify the role of serotonin in these pathways and may lead to preventative treatment strategies.
Find related publications in this database (using NLM MeSH Indexing)
Adult -
Analysis of Variance -
Antiviral Agents - adverse effects Antiviral Agents - therapeutic use
Arginine - analogs & derivatives Arginine - metabolism
Cardiovascular Diseases - epidemiology Cardiovascular Diseases - metabolism
Chromatography, Liquid -
Depression - chemically induced Depression - epidemiology Depression - metabolism
Depressive Disorder - chemically induced Depressive Disorder - epidemiology Depressive Disorder - metabolism
Drug Therapy, Combination -
Female -
Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - metabolism Hepatitis C, Chronic - psychology
Humans -
Interferon-alpha - adverse effects Interferon-alpha - therapeutic use
Male -
Nitric Oxide Synthase - antagonists & inhibitors
Prospective Studies -
Psychiatric Status Rating Scales - statistics & numerical data
Regression Analysis -
Ribavirin - therapeutic use
Risk Factors -
Time Factors -

Find related publications in this database (Keywords)
hepatitis C
IFN-alpha
depression
asymmetric dimethylarginine
symmetric dimethylarginine
cardiovascular risk
© Meduni Graz Impressum